



PATENT
ATTORNEY DOCKET NO. 00786/428002

Certificate of Mailing: Date of Deposit: July 8, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis

Printed name of person mailing correspondence

Janet D'Annunzio-Ellis

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Denise Faustman	Art Unit:	1614
Serial No.:	10/713,679	Examiner:	Not Yet Assigned
Filed:	November 14, 2003	Customer No.:	21559
Title:	SCREENING METHODS TO IDENTIFY TREATMENTS FOR AUTOIMMUNE DISEASE		

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: July 7, 2004



Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 00786/428002 Serial No. 10/713,679 Applicant Denise Faustman Filing Date November 14, 2003 Group 1614 IDS Filed July 8, 2004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. § 1.98(b))						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Sun et al., "MHC class I multimers," <i>Arthritis Res.</i> 3(5):265-269 (2001).					
	Bill et al., "Use of soluble MHC class II/peptide multimers to detect antigen-specific T cells in human disease," <i>Arthritis Res.</i> 4(4):261-265 (2002).					
	Mak et al., "Signaling for survival and apoptosis in the immune system," <i>Arthritis Res.</i> 4 Suppl. 3:S243-S252 (2002).					
	Darzynkiewicz et al., "Use of flow and laser scanning cytometry to study mechanisms regulating cell cycle and controlling cell death," <i>Clin. Lab. Med.</i> 21(4):857-873 (2001).					
	Laakko et al., "Versatility of merocyanine 540 for the flow cytometric detection of apoptosis in human and murine cells," <i>J. Immunol. Methods</i> 261(1-2):129-139 (2002).					
	Prieto et al., "Apoptotic rate: a new indicator for the quantification of the incidence of apoptosis in cell cultures," <i>Cytometry</i> 48(4):185-193 (2002).					
	Allen et al., "Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study.," <i>Diabetes Care</i> 22(10):1703-1707 (1999).					
	Graves et al., "Lack of association between early childhood immunizations and beta-cell autoimmunity.," <i>Diabetes Care</i> 22(10):1694-1697 (1999).					
	Fischer et al., "An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity.," <i>J. Immunol. Methods</i> 259(1-2):159-169 (2002).					
	Lewis et al., "Integrins regulate the apoptotic response to DNA damage through modulation of p53.," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 99(6):3627-3632 (2002).					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 00786/428002 Serial No. 10/713,679 Applicant Denise Faustman Filing Date November 14, 2003 Group 1614 IDS Filed July 8, 2004				
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Xu and Screaton, "MHC/peptide tetramer-based studies of T cell function.," <i>J. Immunol. Methods</i> 268(1):21-28 (2002).					
	Koarada et al., "B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus.," <i>Arthritis Rheum.</i> 42(12)2593-2600 (1999).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						